Libraries and Infrastructure

• State-of-the-art high throughput screening platforms with a variety of high throughput screening and high content screening technologies
• Development of new high throughput screening and cell microarray based chemical biology technologies
• Screening of known drugs for pharmacogenomics on patient-derived cell lines
• Nationally coordinated academic access to state-of-the-art chemoinformatics software as well as expertise with custom program development
• Access to CSC supercomputing capabilities

Libraries

We provide access to a shared small molecule collection of over 140 000 drugs and drug-like compounds that are ready to use for screening. The chemical collections can be divided into two major classes: drugs & known bioactives and chemical diversity libraries. The drugs and known bioactives are ideal for biological profiling, drug repositioning and personalized medicine-type screens while the larger chemical diversity collections are best suited for molecular probe discovery screening. In addition, there is access to genomic libraries.

The drug and known bioactive collections include

• Microsource Spectrum collection (2 000 compounds)
• ENZO FDA-approved library (640 compounds)
• NIH Clinical Collection (450 compounds)
• FIMM set of approved and emerging investigational drugs (527 compounds)

The chemical diversity collections include

• ChemBridge DIVERset (20 000 compounds)
• ChemBridge CNS-Set (10 000 compounds)
• ChemDiv chemical diversity collections (25 000 + 25 000 compounds)
• Specs Consortium collection from (30 000 compounds)
• Tripos diversity collection (6 000 compounds)

The genomic libraries include

• Genome-wide Silencer® Select siRNA library from Ambion
• Genome-wide siRNA library from Qiagen